Hims & Hers Health (NYSE:HIMS) Trading 2.1% Higher - Should You Buy?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price traded up 2.1% on Friday . The stock traded as high as $63.72 and last traded at $62.35. 13,647,829 shares traded hands during trading, a decline of 36% from the average session volume of 21,424,111 shares. The stock had previously closed at $61.07.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price objective for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Piper Sandler reiterated a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Needham & Company LLC lifted their price objective on Hims & Hers Health from $61.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of "Hold" and an average target price of $38.00.

Hims & Hers Health Trading Up 4.3%

The company has a market cap of $14.25 billion, a P/E ratio of 92.60, a PEG ratio of 2.30 and a beta of 2.09. The business has a 50 day moving average price of $47.68 and a 200-day moving average price of $38.96.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The company had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same quarter in the prior year, the business posted $0.05 EPS. The business's revenue was up 110.7% compared to the same quarter last year. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the transaction, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at approximately $6,853,999.52. The trade was a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $58.40, for a total value of $7,482,616.80. Following the completion of the transaction, the chief executive officer now directly owns 89,311 shares in the company, valued at approximately $5,215,762.40. This represents a 58.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 751,034 shares of company stock valued at $36,486,522. 13.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at $30,000. Smartleaf Asset Management LLC lifted its position in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares during the period. Summit Securities Group LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $38,000. Finally, UMB Bank n.a. lifted its position in shares of Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after acquiring an additional 933 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.